WO1999015684A3 - Expression of genes in hematopoietic stem cells in hischaemic conditions - Google Patents

Expression of genes in hematopoietic stem cells in hischaemic conditions Download PDF

Info

Publication number
WO1999015684A3
WO1999015684A3 PCT/GB1998/002885 GB9802885W WO9915684A3 WO 1999015684 A3 WO1999015684 A3 WO 1999015684A3 GB 9802885 W GB9802885 W GB 9802885W WO 9915684 A3 WO9915684 A3 WO 9915684A3
Authority
WO
WIPO (PCT)
Prior art keywords
hischaemic
genes
expression
conditions
stem cells
Prior art date
Application number
PCT/GB1998/002885
Other languages
French (fr)
Other versions
WO1999015684A2 (en
WO1999015684A9 (en
WO1999015684A8 (en
Inventor
Claire Lewis
Katie Mary Binley
Chris Bebbington
Stuart Naylor
Original Assignee
Oxford Biomedica Ltd
Claire Lewis
Katie Mary Binley
Chris Bebbington
Stuart Naylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9720216.2A external-priority patent/GB9720216D0/en
Priority claimed from GBGB9720465.5A external-priority patent/GB9720465D0/en
Priority to CA002303663A priority Critical patent/CA2303663A1/en
Priority to GB0006993A priority patent/GB2345063B/en
Priority to NZ503318A priority patent/NZ503318A/en
Priority to JP2000512973A priority patent/JP2001517453A/en
Priority to KR1020007003066A priority patent/KR20010052076A/en
Priority to EP98946556A priority patent/EP1017838A2/en
Priority to AU93562/98A priority patent/AU747609B2/en
Priority to IL13489798A priority patent/IL134897A0/en
Application filed by Oxford Biomedica Ltd, Claire Lewis, Katie Mary Binley, Chris Bebbington, Stuart Naylor filed Critical Oxford Biomedica Ltd
Publication of WO1999015684A2 publication Critical patent/WO1999015684A2/en
Publication of WO1999015684A3 publication Critical patent/WO1999015684A3/en
Publication of WO1999015684A8 publication Critical patent/WO1999015684A8/en
Publication of WO1999015684A9 publication Critical patent/WO1999015684A9/en
Priority to DE69940318T priority patent/DE69940318D1/en
Priority to CN99811312A priority patent/CN1319139A/en
Priority to CA002343324A priority patent/CA2343324A1/en
Priority to AU62130/99A priority patent/AU6213099A/en
Priority to GB0105483A priority patent/GB2358020A/en
Priority to EP99949142A priority patent/EP1115877B1/en
Priority to KR1020017003650A priority patent/KR20010084913A/en
Priority to JP2000574270A priority patent/JP2002526083A/en
Priority to AT99949142T priority patent/ATE420963T1/en
Priority to IL14182999A priority patent/IL141829A0/en
Priority to PCT/GB1999/003181 priority patent/WO2000017371A1/en
Priority to NO20001487A priority patent/NO20001487L/en
Priority to ZA200101494A priority patent/ZA200101494B/en
Priority to US10/810,262 priority patent/US20040234505A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

A modified haematopoeitic stem cell (MHSC) is described. The MHSC comprises at least one expressable nucleotide sequence of interest (NOI) wherein the or each NOI is operably linked to one or more ischaemia like response element (ILRE).
PCT/GB1998/002885 1997-09-23 1998-09-23 Expression of genes in hematopoietic stem cells in hischaemic conditions WO1999015684A2 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IL13489798A IL134897A0 (en) 1997-09-23 1998-09-23 Expression of genes in hematopoietic stem cells in ischemic conditions
AU93562/98A AU747609B2 (en) 1997-09-23 1998-09-23 Expression of genes in hematopoietic stem cells in hischaemic conditions
CA002303663A CA2303663A1 (en) 1997-09-23 1998-09-23 Expression of genes in hematopoietic stem cells in hischaemic conditions
GB0006993A GB2345063B (en) 1997-09-23 1998-09-23 Method
NZ503318A NZ503318A (en) 1997-09-23 1998-09-23 Modified haemopoietic stem cell comprised of a spliced upstream with a nucleotide sequence of interest to be used as in gene therapy
JP2000512973A JP2001517453A (en) 1997-09-23 1998-09-23 Method
KR1020007003066A KR20010052076A (en) 1997-09-23 1998-09-23 Expression of genes in hematopoietic stem cells in ischaemic conditions
EP98946556A EP1017838A2 (en) 1997-09-23 1998-09-23 Expression of genes in hematopoietic stem cells in hischaemic conditions
EP99949142A EP1115877B1 (en) 1998-09-23 1999-09-22 Polynucleotide constructs and uses thereof
KR1020017003650A KR20010084913A (en) 1998-09-23 1999-09-22 Polynucleotide constructs and uses thereof
JP2000574270A JP2002526083A (en) 1998-09-23 1999-09-22 Polynucleotide constructs and uses thereof
CN99811312A CN1319139A (en) 1998-09-23 1999-09-22 Polynucleotide constructs and uses thereof
IL14182999A IL141829A0 (en) 1998-09-23 1999-09-22 Polynucleotide constructs and uses thereof
DE69940318T DE69940318D1 (en) 1998-09-23 1999-09-22 POLYNUCLEOTIDE CONSTRUCTS AND ITS USES
AT99949142T ATE420963T1 (en) 1998-09-23 1999-09-22 POLYNUCLEOTIDE CONSTRUCTS AND USES THEREOF
PCT/GB1999/003181 WO2000017371A1 (en) 1998-09-23 1999-09-22 Polynucleotide constructs and uses thereof
CA002343324A CA2343324A1 (en) 1998-09-23 1999-09-22 Polynucleotide constructs and uses thereof
AU62130/99A AU6213099A (en) 1998-09-23 1999-09-22 Polynucleotide constructs and uses thereof
GB0105483A GB2358020A (en) 1998-09-23 1999-09-22 Polynucleotide constructs and uses thereof
NO20001487A NO20001487L (en) 1997-09-23 2000-03-22 Expression of genes in hematopoietic stem cells in ischemic states
ZA200101494A ZA200101494B (en) 1998-09-23 2001-02-22 Polynucleotide contructs and uses therof.
US10/810,262 US20040234505A1 (en) 1998-09-23 2004-03-26 Polynucleotide constructs and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9720216.2 1997-09-23
GBGB9720216.2A GB9720216D0 (en) 1997-09-23 1997-09-23 Delivery of therapeutic genes to haematopoietic stem cells
GBGB9720465.5A GB9720465D0 (en) 1997-09-25 1997-09-25 Dual-virus vectors
GB9720465.5 1997-09-25

Publications (4)

Publication Number Publication Date
WO1999015684A2 WO1999015684A2 (en) 1999-04-01
WO1999015684A3 true WO1999015684A3 (en) 1999-06-10
WO1999015684A8 WO1999015684A8 (en) 1999-08-12
WO1999015684A9 WO1999015684A9 (en) 1999-09-16

Family

ID=26312300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/002885 WO1999015684A2 (en) 1997-09-23 1998-09-23 Expression of genes in hematopoietic stem cells in hischaemic conditions

Country Status (11)

Country Link
EP (1) EP1017838A2 (en)
JP (1) JP2001517453A (en)
KR (1) KR20010052076A (en)
CN (1) CN1303442A (en)
AU (1) AU747609B2 (en)
CA (1) CA2303663A1 (en)
GB (1) GB2345063B (en)
IL (1) IL134897A0 (en)
NO (1) NO20001487L (en)
NZ (1) NZ503318A (en)
WO (1) WO1999015684A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002526083A (en) * 1998-09-23 2002-08-20 オックスフォード バイオメディカ（ユーケイ）リミテッド Polynucleotide constructs and uses thereof
US7148035B1 (en) 1998-11-18 2006-12-12 Oxford Biomedica (Uk) Limited Polypeptide
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
EP2042598A1 (en) 1998-11-18 2009-04-01 Oxford Biomedica (UK) Limited 5T4 tumour-associated antigen for use in tumour immunotherapy
GB9906615D0 (en) * 1999-03-22 1999-05-19 Oxford Biomedica Ltd Vector
WO2001066150A2 (en) * 2000-03-07 2001-09-13 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cel ls by rd114 pseudotyped retroviral vector particles
US6849454B2 (en) 2000-03-07 2005-02-01 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (en) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
GB0203419D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
CA2965865C (en) 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
JP4572320B2 (en) * 2004-02-23 2010-11-04 財団法人大阪産業振興機構 Recombinant human cell and method for evaluating at least one of induction of drug metabolizing enzyme and drug metabolism using the recombinant human cell
EP2045268B1 (en) 2005-05-13 2011-09-21 Oxford BioMedica (UK) Limited Mhc class I and II peptide antigens derived from tumour antigen 5t4
EP2079832A4 (en) 2006-05-17 2010-08-04 Cognate Therapeutics Inc Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
MX360110B (en) 2012-04-20 2018-10-23 Merus Nv Methods and means for the production of ig-like molecules.
JP7007273B2 (en) 2015-12-22 2022-01-24 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） Improved complex double-recombinant AAV vector system for gene therapy
CN113699146A (en) * 2020-05-22 2021-11-26 深圳市深研生物科技有限公司 Promoter element, retroviral genome transcription cassette comprising the same, and vector

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002556A1 (en) * 1991-07-26 1993-02-18 University Of Rochester Cancer therapy utilizing malignant cells
WO1995006120A1 (en) * 1993-08-25 1995-03-02 Rhone-Poulenc Rorer S.A. Recombinant cells from the monocyte-macrophage cell line for gene therapy
WO1995021927A2 (en) * 1994-02-15 1995-08-17 Isis Innovation Limited Targeting gene therapy
WO1995029704A1 (en) * 1994-04-28 1995-11-09 Scott Freeman Cell lines obtained by in vivo migration and by fusion with autoimmune cells
WO1996020276A1 (en) * 1994-12-23 1996-07-04 Sri International Tissue specific hypoxia regulated therapeutic constructs
WO1998015294A1 (en) * 1996-10-09 1998-04-16 Oxford Biomedica (Uk) Limited Mononuclear phagocytes in therapeutic drug delivery

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002556A1 (en) * 1991-07-26 1993-02-18 University Of Rochester Cancer therapy utilizing malignant cells
WO1995006120A1 (en) * 1993-08-25 1995-03-02 Rhone-Poulenc Rorer S.A. Recombinant cells from the monocyte-macrophage cell line for gene therapy
WO1995021927A2 (en) * 1994-02-15 1995-08-17 Isis Innovation Limited Targeting gene therapy
WO1995029704A1 (en) * 1994-04-28 1995-11-09 Scott Freeman Cell lines obtained by in vivo migration and by fusion with autoimmune cells
WO1996020276A1 (en) * 1994-12-23 1996-07-04 Sri International Tissue specific hypoxia regulated therapeutic constructs
WO1998015294A1 (en) * 1996-10-09 1998-04-16 Oxford Biomedica (Uk) Limited Mononuclear phagocytes in therapeutic drug delivery

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BILBAO G. ET AL.: "Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo.", FASEB J., vol. 11, 11 July 1997 (1997-07-11), pages 624 - 634, XP002091318 *
BORIS-LAWRIE K. & TEMIN H.M.: "The retroviral vector", 1994, "GENE THERAPY FOR NEOPLASTIC DISEASES", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK, XP002099949 *
HWU P. & ROSENBERG S.A.: "The use of gene-modified tumor-infiltrating lymphocytes for cancer therapy", 1994, "GENE THERAPY FOR NEOPLASTIC DISEASES", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK, XP002099947 *
LEWIS J ET AL: "ROLE OF MACROPHAGES IN TUMOUR ANGIOGENESIS: REGULATION BY HYPOXIA", PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND. MEETING, vol. 182, 2 July 1997 (1997-07-02), pages 1A, XP002056969 *
POUWELS P.H. ET AL.: "Cloning vectors (Laboratory manual)", 1985, ELSVIER, AMSTERDAM, XP002099948 *

Also Published As

Publication number Publication date
JP2001517453A (en) 2001-10-09
WO1999015684A2 (en) 1999-04-01
IL134897A0 (en) 2001-05-20
EP1017838A2 (en) 2000-07-12
CA2303663A1 (en) 1999-04-01
WO1999015684A9 (en) 1999-09-16
GB2345063A (en) 2000-06-28
AU9356298A (en) 1999-04-12
KR20010052076A (en) 2001-06-25
AU747609B2 (en) 2002-05-16
NZ503318A (en) 2001-11-30
GB0006993D0 (en) 2000-05-10
NO20001487L (en) 2000-05-23
WO1999015684A8 (en) 1999-08-12
CN1303442A (en) 2001-07-11
NO20001487D0 (en) 2000-03-22
GB2345063B (en) 2002-07-24

Similar Documents

Publication Publication Date Title
WO1999015684A3 (en) Expression of genes in hematopoietic stem cells in hischaemic conditions
WO1999012950A3 (en) Improvements in or relating to stability of plant starches
AU9200398A (en) A process to study changes in gene expression in granulocytic cells
AU4772697A (en) Subtilase variants and compositions
WO2000005381A3 (en) Expression of enzymes involved in cellulose modification
DE69319771D1 (en) Immobilized enzyme electrode, composition for its production and electrically conductive enzymes
WO2000035030A3 (en) Battery network with compounded interconnections
DE69535352D1 (en) EXPRESSION OF BAZILLUS THURINGIENSIS CRY PROTEINS IN PLANT PLASTIDES
BR9608647A (en) DNA amylase and detergent composition
AU1603899A (en) Mutant (bacillus licheniformis) alpha-amylase
WO2001068836A3 (en) Methods and compositions for rna interference
WO2000024907A3 (en) Library of novel "unnatural" natural products
AU3675195A (en) Oligonucleotide prodrugs
WO2000004158A3 (en) Compositions and methods for fumonisin detoxification
EP1287160A4 (en) Measurements of enzymatic activity in a single, individual cell in population
AU9200298A (en) A process to study changes in gene expression in stem cells
WO2000026391A3 (en) Trans-species transfer of apoptotic genes and transgenic plants developed thereby
HUP9900451A3 (en) Improved integration of exogenous dna delivered to eukaryotic cells
AU4595499A (en) Nonsymbiotic plant hemoglobins to maintain cell energy status
WO2002055658A3 (en) Identification and characterization of an anthocyanin mutant (ant1) in tomato
CA2242574A1 (en) Glutenin genes and their uses
AUPM310493A0 (en) Improvements in relation to row cultivators
WO2000022092A3 (en) Materials and methods for the modification of plant cell wall polysaccharides
WO1999002669A3 (en) Production of polyketides in plants
NZ515795A (en) Compositions affecting programmed cell death and their use in the modification of forestry plant development

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134897

Country of ref document: IL

Ref document number: 98811427.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: PUBLISHED ABSTRACT REPLACED BY CORRECT ABSTRACT

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 167-169, DESCRIPTION, REPLACED BY CORRECT PAGES 167-169; PAGE 2/43, DRAWINGS, REPLACED BY CORRECT PAGE 2/43

COP Corrected version of pamphlet

Free format text: PAGES 163, 181-183 AND 191, ANNEX, REPLACED BY CORRECTED PAGES 163,181-183 AND 191; PAGE 191, ANNEX, DELETED; PAGES 193-195, CLAIMS, RENUMBERED AS PAGES 192-194

WWE Wipo information: entry into national phase

Ref document number: 503318

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2303663

Country of ref document: CA

Ref document number: 2303663

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 200006993

Country of ref document: GB

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020007003066

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 93562/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998946556

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1-97, DESCRIPTION, REPLACED BY NEW PAGES 1-97; PAGES 98-184, ANNEX DESCRIPTION, REPLACED BY NEW PAGES 98-184; PAGES 185-190, ANNEX CLAIMS, REPLACED BY NEW PAGES 185-190; PAGES 1/35-35/35, ANNEX DRAWINGS, REPLACED BY NEW PAGES 1/35-35/35; PAGES 1-4, SEQUENCE LISTING, REPLACED BY NEW PAGES 1-4, ANNEX SEQUENCE LISTING; PAGES 192-194, CLAIMS, REPLACED BY NEW PAGES 192-194; PAGES 1/43-43/43, DRAWINGS, REPLACED BY NEW PAGES 1/43-43/43

WWE Wipo information: entry into national phase

Ref document number: 09509129

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998946556

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007003066

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 93562/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020007003066

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998946556

Country of ref document: EP